# Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

> **NCT05572645** · — · COMPLETED · sponsor: **Fudan University** · enrollment: 333 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib Plus Trastuzumab
- **DRUG:** Pertuzumab Plus Trastuzumab

## Key facts

- **NCT ID:** NCT05572645
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05572645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05572645, "Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05572645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*